Class action lawsuit filed against Boston Scientific after stock drops 17.6% on weak sales and guidance

Boston Scientific faces a class action lawsuit alleging securities fraud following its February 2026 announcement of disappointing Q4 2025 sales and weak 2026 guidance. The company cited slower market growth and increased competition as reasons for the shortfall, causing its stock to plunge 17.6% in one day. Investors who bought Boston Scientific shares during the class period can seek lead plaintiff status by May 4, 2026. The lawsuit highlights potential legal risks for the company amid its financial struggles.